Companies
SciSure
a Netherlands-rooted digital lab platform whose inventory module tracks every sample, reagent and material with instant lookup and automatic expiration alerts, integrated with experiment records, and which extends to instrument integrations such as Eppendorf RackScan.
- Country
- Netherlands
EU
Coverage
| CN | EU | US | |
|---|---|---|---|
| digital-it | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Multiple private funding rounds, including a 2012 Seed round and a 2023 private equity majority growth investment from Strattam Capital. | biobase.whitefordresearch.com |
| Headcount | 86-96 employees | getlatka.com |
| Revenue | $10.6M estimated annual revenue (as of 2025) | getlatka.com |
| Certification | ISO/IEC 27001 certified | scisure.com |
| Regulatory approval | Supports FDA 21 CFR Part 11, GxP, and HIPAA compliance requirements. | scisure.com |
| Headquarters | Boston, Massachusetts, United States | getlatka.com |
Independent sources: biobase.whitefordresearch.com · getlatka.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Lab-equipment management & procurement | digital-it | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.